| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Clinical Cancer Prevention [X-C. X., S. M. L.] and Thoracic/Head & Neck Medical Oncology [W. Y. L. W., R. L.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Departments of Dermatology [L. G., J. E. W.] and Dermatopathology [S. C. B.], Baylor College of Medicine, Houston, Texas 77030; Austin, Texas 78745 [W. M. R.]; and Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, Arizona 85724 [D. S. A.]
| ABSTRACT |
|---|
|
|
|---|
and -
and RXR-
, -ß, and -
) were moderate to very strong in normal skin, with higher expressions in spinous and granular layers than in the basal layer. RAR-ß expression was weak or absent in normal and lesion samples. All five receptors expressed in the skin were suppressed progressively from normal skin to premalignant skin (AK) to invasive skin SCC. Specific receptor decreases in lesions relative to normal skin ranged from 75% (RXR-ß) to 96% (RAR-
) in SCC and from 37% (RAR-
) to 68% (RXR-ß) in AK. The degree of suppression of RXR-
and RAR-
, the two predominant retinoid receptors in skin, was relatively less for RXR-
(58% versus 86%; P = 0.015) and relatively greater for RAR-
(37% versus 89%; P = 0.0001) between AK and SCC, suggesting that suppression of RXR-
may be an earlier event and expression of RAR-
may be a later event of multistep squamous skin carcinogenesis. Our results indicate that suppressed expression of retinoid receptors occurs early (in AK) and is associated with progression of squamous skin carcinogenesis to SCC. | Introduction |
|---|
|
|
|---|
Although most early skin SCCs and BCCs are controlled successfully with conservative local therapy, they still are responsible for profound quality of life consequences, such as substantial pain, cosmetic morbidity, and medical costs (4) . Therefore, new strategies to prevent skin cancer are necessary and are being developed. One of the best studied of these new approaches is retinoid chemoprevention, which has established clinical activity in several sites of epithelial carcinogenesis, including the skin (5, 6, 7, 8) .
Retinoids exert their effects primarily through two subfamilies of the steroid/thyroid hormone receptor superfamily, the RARs and RXRs. There are three types each of RARs (RAR-
, -ß, and -
) and RXRs (RXR-
, -ß, and -
), and all are nuclear, ligand-dependent, DNA-binding transcriptional transactivator proteins (9)
.
The various RAR and RXR subtypes are encoded by different genes, are highly conserved in evolution, and display distinct spatiotemporal expression patterns in early and adult stages of development, suggesting that each receptor has distinct physiological functions. RAR-
is expressed in most tissues. RAR-ß has a more restricted distribution pattern, which does not include the skin. RAR-
is expressed mainly in the skin, accounting for 87% of the RAR protein in that tissue. RXR-
is the skins predominant RXR, accounting for 90% of the RXR protein in the skin (10)
. Therefore, it is highly likely that the RAR-
/RXR-
heterodimer is the principle transducer of the retinoid signal in human skin (11)
.
We designed our present analysis of retinoid receptor status in premalignant and malignant skin lesions (relative to that in adjacent normal skin) to assess possible relationships among the levels of these receptors and cancer development and progression. This information is important for improving our ability to predict responsiveness to retinoid treatment. To our knowledge, this is the first systematic comparative analysis of all six retinoid receptor expressions in human skin SCCs and BCCs, AK, and normal skin. Isolated findings of retinoid receptor expressions in human skin (10
, 12)
and a decrease in RAR-
expression in skin SCC (13)
have been reported.
| Materials and Methods |
|---|
|
|
|---|
We used a nonradioactive in situ hybridization method based on digoxygenin-labeled antisense riboprobes prepared for each of the six receptors, as described previously (14 , 15) . The quality and specificity of the digoxigenin-labeled probes were determined by Northern blot analysis (14) . The specificity of the binding of antisense riboprobes was verified by negative control sections to which sense probes were hybridized or no probe was hybridized. These controls were found to be negative. The stained sections were reviewed with a Nikon microscope. Lesion or normal skin staining within each section was scored from 04 as follows: (a) 0, no staining; (b) 1, weak staining; (c) 2, moderate staining; (d) 3, strong staining; and (e) 4, very strong staining.
| Results |
|---|
|
|
|---|
and -
and RXR-
, -ß, and -
expressions ranged from moderate to very strong in normal skin. However, the patterns of receptor expression were not consistent throughout the epidermal layers, with generally higher expressions in the spinous and granular layers than in the basal layer. RAR-ß expression ranged from weak to absent in normal skin and in the lesion samples as well.
We then analyzed receptor expression in 38 AK and 28 SCC specimens by in situ hybridization (Figs. 1
and 2
). The staining category (scores, 04) of each of 38 AK specimens and 28 SCC specimens is summarized in Table 1
, and the number of cases in which the staining in AK or SCC was lower than that in the corresponding adjacent normal specimen was determined and is presented in Table 2
.
|
|
|
|
suppression occurred in <50% of samples) compared with normal skin (Table 2
suppression (Table 2)
) of samples (Table 2)| Discussion |
|---|
|
|
|---|
) to 96% (RAR-
). We found that expression of the two predominant skin receptors, RAR-
and RXR-
, was reduced in 89% and 86% of SCC lesions, respectively. RXR-
suppression occurred in 58% of AKs compared with 86% of SCCs (P = 0.015,
2 test), indicating that this is an earlier event during carcinogenesis, whereas RAR-
suppression occurred in 37% of AKs compared with 89% of SCCs (P = 0.0001,
2), indicating that this is a later event. All these data support our conclusion that a progressive decrease in the expressions of RAR-
, RAR-
, RXR-
, RXR-ß, and RXR-
occurs in carcinogenic progression from normal skin to AK to SCC.
Retinoids and their nuclear receptors are critically important to skin physiology. Several groups have previously described the expressions of RARs and RXRs in normal human skin (10, 11, 12, 13)
. RAR-
is highly expressed, followed by RAR-
whereas RAR-ß is expressed at low levels or is not expressed at all (10
, 16)
. RXR-
predominates, and RXR-ß can be detected; but neither RXR-
message or protein has been detected previously in normal skin (10)
. Except for those regarding RXR-
expression, our results are consistent with these previously reported findings on RAR-
and RXR-
expression patterns in normal skin. Our samples of normal skin (which were from skin adjacent to SCCs) did express the RXR-
transcript. This difference between our report and previous reports probably reflects the greater sensitivity of in situ hybridization (our method) as compared with Northern blotting (the method used in previous studies). In situ hybridization is very sensitive because it can detect mRNA in individual cells.
We are aware of only one isolated previous report of nuclear retinoid receptor expression in SCC, which showed suppressed RAR-
(13)
. Altered expression levels or aberrant function of retinoid receptors, however, has been associated with several other epithelial neoplasms, including head and neck cancer (RAR-ß; Ref. 15
), breast cancer (RAR-
and -ß; Ref. 17
), esophageal cancer (RAR-ß; Ref. 18
), non-small cell lung cancer (RAR-ß, -
, and RXR-
; Ref. 19
), prostate cancer (RAR-ß and RXR-ß; Ref. 20
), and dysplastic nevi (RXR-ß; Ref. 21
). The expression of RAR-
, RAR-
, and RXR-
mRNA in mouse skin was found to decrease a few hours after exposure of the skin to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (22)
, and RAR-
and -
were progressively lost during mouse skin carcinogenesis (23)
. The profound loss we report here in human skin SCC of expression of all retinoid receptors found in normal skin has not been reported for any other cancer, including non-cutaneous SCCs. Consistent with aberrant RA signaling in skin SCC, we recently found significant suppression of the RA-regulated gene TIG-3 in skin SCC (24)
. Because retinoid receptors have been implicated in differentiation of normal keratinocytes in vitro (25)
and skin epidermis in vivo (26)
, it is plausible that decreased expression of these receptors may be the cause of dysregulation of differentiation and may contribute to early stages of skin carcinogenesis.
The mechanism underlying the suppression of nuclear retinoid receptor expression in the development and progression of human squamous carcinogenesis of the skin remains unknown. Recent studies, however, have shown that exposure of human skin to low levels of UV irradiation results in a reduction in RAR-
and RXR-
mRNA and protein, which can be prevented by RA treatment (27)
. Subsequently, it was shown that UV irradiation inhibits the synthesis of RAR-
and RXR-
protein and that these receptors are substrates for ubiquitination and proteasome-mediated degradation (28)
.
Our present results suggest the following hypotheses: (a) the loss of receptor expression may result in diminished ability of epidermal cells to respond to physiological levels of RA, and this may contribute to SCC development; and (b) pharmacological RA levels may restore the ability of skin SCC cells to use RA by saturating the remaining signaling machinery and thus up-regulating the skin RARs. These hypotheses are consistent with the positive results of a recent definitive Phase III retinol trial (7) . We are assessing these hypotheses in an ongoing National Cancer Institute skin Phase III trial underway at The University of Texas M. D. Anderson Cancer Center.
| FOOTNOTES |
|---|
1 Supported in part by NIH Grants 5 P01 CA68233, 2 P01 CA27502, and CA16672 from the National Cancer Institute and Grant ATP15-067 from the Texas Higher Education Coordinating Board. ![]()
2 Present address: Clinical Pathology Associates, 9200 Wall Street, Austin, TX 78754. ![]()
3 To whom requests for reprints should be addressed, at Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030. Phone: (713) 792-8740; Fax: (713) 796-8655; E-mail: rlotan{at}mdanderson.org ![]()
4 The abbreviations used are: SCC, squamous cell carcinoma; BCC, basal cell carcinoma; RAR, retinoic acid receptor; RXR, retinoid X receptor; AK, actinic keratosis; RA, retinoic acid. ![]()
Received 1/ 4/01. Accepted 4/16/01.
| REFERENCES |
|---|
|
|
|---|
expression in normal and neoplastic skin. Am. J. Pathol., 140: 1463-1471, 1992.[Abstract]
and
retinoic acid receptors in skin. J. Investig. Dermatol., 93: 818-820, 1989.[Medline]
retinoid receptors are down-regulated in dysplastic nevi. Proc. Am. Assoc. Cancer Res., 41: 510 2000.
and retinoid X receptor
in human keratinocytes. Cancer Res., 60: 2247-2252, 2000.This article has been cited by other articles:
![]() |
P.-L. So, M. A. Fujimoto, and E. H. Epstein Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis Mol. Cancer Ther., May 1, 2008; 7(5): 1275 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. B. Janakiram, I. Cooma, A. Mohammed, V. E. Steele, and C. V. Rao -Ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-{alpha} in human colon cancer cells Mol. Cancer Ther., January 1, 2008; 7(1): 181 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chakravarti, R. Lotan, A. H. Diwan, C. L. Warneke, M. M. Johnson, and V. G. Prieto Decreased Expression of Retinoid Receptors in Melanoma: Entailment in Tumorigenesis and Prognosis Clin. Cancer Res., August 15, 2007; 13(16): 4817 - 4824. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. Cancer Res., September 15, 2006; 66(18): 9299 - 9307. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Rebel, N. Kram, A. Westerman, S. Banus, H. J. van Kranen, and F. R. de Gruijl Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice Carcinogenesis, December 1, 2005; 26(12): 2123 - 2130. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-L. So, K. Lee, J. Hebert, P. Walker, Y. Lu, J. Hwang, L. Kopelovich, M. Athar, D. Bickers, M. Aszterbaum, et al. Topical Tazarotene Chemoprevention Reduces Basal Cell Carcinoma Number and Size in Ptch1+/- Mice Exposed to Ultraviolet or Ionizing Radiation Cancer Res., July 1, 2004; 64(13): 4385 - 4389. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Alberts, J. Ranger-Moore, J. Einspahr, K. Saboda, P. Bozzo, Y. Liu, X.-c. Xu, R. Lotan, J. Warneke, S. Salasche, et al. Safety and Efficacy of Dose-Intensive Oral Vitamin A in Subjects with Sun-Damaged Skin Clin. Cancer Res., March 15, 2004; 10(6): 1875 - 1880. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Hansen, D. Brown, V. Virador, T. Tanaka, F. Andreola, K. Strain, B. Dancheck, R. Riley, J. M. Arbeit, L. M. De Luca, et al. A PMLRARA Transgene Results in a Retinoid-deficient Phenotype Associated with Enhanced Susceptibility to Skin Tumorigenesis Cancer Res., September 1, 2003; 63(17): 5257 - 5265. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Y. Fan, T. E. Spencer, N. Wang, M. P. Moyer, and R. S. Chapkin Chemopreventive n-3 fatty acids activate RXR{alpha} in colonocytes Carcinogenesis, September 1, 2003; 24(9): 1541 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kusmartsev, F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich All-trans-Retinoic Acid Eliminates Immature Myeloid Cells from Tumor-bearing Mice and Improves the Effect of Vaccination Cancer Res., August 1, 2003; 63(15): 4441 - 4449. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. M. Blokx, J. V. Smit, P. C. M. de Wilde, P. C. M. van de Kerkhof, D. J. Ruiter, and E. M. G. J. de Jong Immunohistochemical Effects of Temporary Cessation of Long-term Acitretin Treatment in Keratinocytic Intraepidermal Neoplasia of Renal Transplant Recipients Arch Dermatol, May 1, 2003; 139(5): 671 - 673. [Full Text] [PDF] |
||||
![]() |
J. Huang, W. C. Powell, A. C. Khodavirdi, J. Wu, T. Makita, R. D. Cardiff, M. B. Cohen, H. M. Sucov, and P. Roy-Burman Prostatic Intraepithelial Neoplasia in Mice with Conditional Disruption of the Retinoid X Receptor{alpha} Allele in the Prostate Epithelium Cancer Res., August 15, 2002; 62(16): 4812 - 4819. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Clifford, E. Walch, X. Yang, X. Xu, D. S. Alberts, G. L. Clayman, A. K. El-Naggar, R. Lotan, and S. M. Lippman Suppression of Type I Interferon Signaling Proteins Is an Early Event in Squamous Skin Carcinogenesis Clin. Cancer Res., July 1, 2002; 8(7): 2067 - 2072. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E.W. Cohen and E. E. Vokes Searching for a Standard J. Clin. Oncol., January 15, 2002; 20(2): 359 - 361. [Full Text] [PDF] |
||||
![]() |
D. M. Shin, B. S. Glisson, F. R. Khuri, J. L. Clifford, G. Clayman, S. E. Benner, A. A. Forastiere, L. Ginsberg, D. Liu, J. J. Lee, et al. Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer J. Clin. Oncol., January 15, 2002; 20(2): 364 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hatoum, M. E. El-Sabban, J. Khoury, S. H. Yuspa, and N. Darwiche Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis Carcinogenesis, December 1, 2001; 22(12): 1955 - 1963. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |